Goldman Sachs’s Acumen Pharmaceuticals ABOS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $388K | Buy |
334,683
+138,476
| +71% | +$161K | ﹤0.01% | 4401 |
|
|
2025
Q1 | $216K | Sell |
196,207
-22,937
| -10% | -$25.2K | ﹤0.01% | 4647 |
|
|
2024
Q4 | $377K | Buy |
219,144
+73,283
| +50% | +$126K | ﹤0.01% | 4430 |
|
|
2024
Q3 | $362K | Buy |
145,861
+94,809
| +186% | +$235K | ﹤0.01% | 4263 |
|
|
2024
Q2 | $124K | Sell |
51,052
-266,852
| -84% | -$646K | ﹤0.01% | 4473 |
|
|
2024
Q1 | $1.29M | Buy |
317,904
+203,172
| +177% | +$823K | ﹤0.01% | 3465 |
|
|
2023
Q4 | $441K | Buy |
114,732
+57,433
| +100% | +$221K | ﹤0.01% | 4021 |
|
|
2023
Q3 | $238K | Buy |
57,299
+43,727
| +322% | +$181K | ﹤0.01% | 4194 |
|
|
2023
Q2 | $65.3K | Sell |
13,572
-28,730
| -68% | -$138K | ﹤0.01% | 4637 |
|
|
2023
Q1 | $172K | Buy |
42,302
+25,311
| +149% | +$103K | ﹤0.01% | 4565 |
|
|
2022
Q4 | $91.8K | Sell |
16,991
-5,626
| -25% | -$30.4K | ﹤0.01% | 4695 |
|
|
2022
Q3 | $227K | Sell |
22,617
-5,269
| -19% | -$52.9K | ﹤0.01% | 4667 |
|
|
2022
Q2 | $131K | Sell |
27,886
-306,309
| -92% | -$1.44M | ﹤0.01% | 5031 |
|
|
2022
Q1 | $1.31M | Buy |
334,195
+10,931
| +3% | +$42.8K | ﹤0.01% | 3912 |
|
|
2021
Q4 | $2.19M | Buy |
323,264
+259,629
| +408% | +$1.75M | ﹤0.01% | 3442 |
|
|
2021
Q3 | $946K | Buy |
+63,635
| New | +$946K | ﹤0.01% | 4013 |
|